Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) EBIT Margin (2016 - 2025)

Cytosorbents (CTSO) has disclosed EBIT Margin for 14 consecutive years, with 30.17% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin rose 2591.0% year-over-year to 30.17%, compared with a TTM value of 38.11% through Sep 2025, up 2401.0%, and an annual FY2024 reading of 47.16%, up 5562.0% over the prior year.
  • EBIT Margin was 30.17% for Q3 2025 at Cytosorbents, up from 37.59% in the prior quarter.
  • Across five years, EBIT Margin topped out at 26.91% in Q1 2021 and bottomed at 111.17% in Q3 2022.
  • Average EBIT Margin over 5 years is 64.26%, with a median of 56.08% recorded in 2024.
  • The sharpest move saw EBIT Margin tumbled -6665bps in 2021, then soared 6779bps in 2024.
  • Year by year, EBIT Margin stood at 88.68% in 2021, then rose by 24bps to 67.69% in 2022, then plummeted by -60bps to 108.54% in 2023, then surged by 62bps to 40.75% in 2024, then rose by 26bps to 30.17% in 2025.
  • Business Quant data shows EBIT Margin for CTSO at 30.17% in Q3 2025, 37.59% in Q2 2025, and 44.54% in Q1 2025.